Lifestance Health Group, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Teresa Deluca, a Director of LifeStance Health Group, Inc., sold 20,441 shares of common stock on August 13, 2026 for $12.23 per share.
NASDAQ
Kenneth A Burdick, a Director of LifeStance Health Group, Inc., sold 500,000 shares of common stock on August 11, 2026 for $11.51 per share.
NASDAQ
Vukasin Paunovich, Chief Technology Officer of LifeStance Health Group, Inc., sold 44,394 shares of common stock on August 10, 2026 for $10.85 per share.
NASDAQ
Tpg Gp A, Llc and 2 others reported changes in beneficial ownership of LifeStance Health Group, Inc. common stock on August 10, 2026.
NASDAQ
Lisa K Miller, Chief Operating Officer of LifeStance Health Group, Inc., sold 47,912 shares of common stock on August 10, 2026 for $10.85 per share.
NASDAQ
Kenneth A Burdick, a Director of LifeStance Health Group, Inc., received 45,495 shares of common stock on July 6, 2026.
NASDAQ
Director Eric Palmer of LifeStance Health Group, Inc. acquired 17,746 restricted stock units on July 2, 2026.
NASDAQ
LifeStance Health Group, Inc. Director Robert Bessler acquired 17,746 restricted stock units.
NASDAQ
LifeStance Health Group, Inc. reports that Director Sarah Personette acquired 17,746 restricted stock units on July 2, 2026.
NASDAQ
Teresa DeLuca, a Director at LifeStance Health Group, Inc., acquired 17,746 restricted stock units on July 2, 2026.
NASDAQ
Director Thurman Justice acquired 35,492 restricted stock units of LifeStance Health Group, Inc. on July 2, 2026.
NASDAQ
Lori Goltermann, a Director at LifeStance Health Group, Inc., acquired 35,492 restricted stock units on July 2, 2026.
NASDAQ
Robert Bessler, a Director at LifeStance Health Group, Inc., reported the sale of a significant number of common shares on June 26, 2026.
NASDAQ
Chief Technology Officer Vukasin Paunovich reported the withholding of 17,456 shares to satisfy tax obligations upon RSU vesting.
NASDAQ
Director Robert Bessler reported the sale of 575,034 shares of LifeStance Health Group, Inc. common stock.
NASDAQ
Director Eric Shuey reported the sale of 243,362 shares of LifeStance Health Group, Inc. common stock at an average price of $8.02.
NASDAQ
Director Darren M. Black reports the sale of 5,899,661 shares of LifeStance Health Group, Inc. by affiliated Summit Partners entities.
NASDAQ
Director Robert Bessler sold 75,000 shares of LifeStance Health Group, Inc. common stock via Rule 10b5-1 trading plans.
NASDAQ
Director Robert Bessler reported the sale of 69,899 shares of LifeStance Health Group, Inc. common stock via Rule 10b5-1 trading plans.
NASDAQ
Director Robert Bessler reported a sale of LifeStance Health Group, Inc. common stock totaling 5,100 shares for approximately $35,700.
NASDAQ
Ryan Pardo, Chief Legal Officer and Secretary of LifeStance Health Group, Inc., reported transactions involving common stock and beneficial ownership changes.
NASDAQ
LifeStance Health Group's CFO, Ryan McGroarty, had 24,255 shares withheld for tax obligations following the vesting of restricted stock units.
NASDAQ
LifeStance Health Group CFO Ryan McGroarty reported the withholding of 47,594 common shares to cover tax obligations from vested restricted stock units.
NASDAQ
TPG GP A, a 10% owner and director, reported the future sale of over 20 million shares of LifeStance Health Group common stock at $7.01 per share, executed under a Rule 10b5-1 plan.
NASDAQ
LifeStance Health Group Director Darren M. Black reported the sale of over 4.3 million shares of common stock for $7.01 per share, totaling approximately $30.25 million.
NASDAQ
LifeStance Health Group Director Robert Bessler reported sales of common stock totaling 121,643 shares across multiple entities under a pre-arranged 10b5-1 plan.
NASDAQ
LifeStance Health Group Director Robert Bessler reported the sale of 9,663 shares of common stock across direct and indirect holdings at a weighted average price of $7.00 per share.
NASDAQ
LifeStance Health Group's Chief People Officer, Ann Varanakis, sold 50,000 shares of common stock for approximately $345,000.
NASDAQ
LifeStance Health Group Director Robert Bessler reported multiple sales of common stock totaling 92,001 shares in December 2025 under a Rule 10b5-1 plan.
NASDAQ
LifeStance Health Group's Executive Vice President, Lisa K. Miller, sold 57,240 shares of common stock at a weighted average price of $6.43 per share.